Following MCC950 therapy, we observed that NLRP3 and IL-1β expression were suppressed, and that in Ang II-infused animals, NLRP3 suppression reduced retinopathy and dysfunction (Figs. 2, 3). This evidence concerns the gene NLRP3 and retinal disorder.